ValitaCell demonstrates the value of disciplined company-building in life sciences: identifying a high-friction problem in bioprocess development and delivering tools that improve speed, throughput and confidence in decision-making.

ValitaCell developed platforms such as Quantum, ChemStress® and CellAi®, and brought products like Valita®Titer to market to support biologics and cell therapy workflows.

In 2022, ValitaCell was acquired by Beckman Coulter Life Sciences, further validating the strength of its technology and market relevance

The ValitaCell journey reflects the practical advantage of partnering with investors who understand both the technical realities and the commercial path required to build enduring companies.